AstraZeneca has reported top-line results from a Phase IIIb trial evaluating a 40mg dose of Crestor (rosuvastatin) compared with a 80mg dose of atorvastatin on the progression of atherosclerosis in high-risk patients.

The 104-week, randomised, double-blind, parallel group, multi-centre study involved around 1,300 patients, and demonstrated that the tolerability and efficacy of Crestor were in line with previous studies and approved product labelling.

The primary efficacy results showed a change from baseline in per cent atheroma volume of the targeted coronary artery as evaluated by intravascular ultrasound, and greater reduction in favour of Crestor versus atorvastatin.

The secondary intravascular ultrasound measure demonstrated a change from baseline in total atheroma volume within the targeted coronary artery.